Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Other Non Operating Income (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Other Non Operating Income data on record, last reported at $151993.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 194.8% year-over-year to $151993.0; the TTM value through Sep 2025 reached -$263986.0, up 73.01%, while the annual FY2024 figure was -$200000.0, 9.29% up from the prior year.
  • Other Non Operating Income reached $151993.0 in Q3 2025 per COEP's latest filing, up from -$338460.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $156801.0 in Q4 2022 and bottomed at -$3.4 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is -$321603.3, with a median of $25.5 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: tumbled 716.77% in 2023, then soared 247400.0% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $16.0 in 2021, then surged by 979906.25% to $156801.0 in 2022, then crashed by 716.77% to -$967102.0 in 2023, then surged by 80.46% to -$188933.0 in 2024, then soared by 180.45% to $151993.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $151993.0 in Q3 2025, -$338460.0 in Q2 2025, and $111414.0 in Q1 2025.